Price$4.44+0.14 (+3.26%)
02:15 PM07:45 PM
News · 26 weeks37+450%
2025-11-022026-04-26
Mix2390d
- SEC Filings7(30%)
- Other7(30%)
- Insider5(22%)
- Earnings3(13%)
- Analyst1(4%)
Latest news
25 items- SECAvita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Names Cary Vance as Chief Executive OfficerBoard appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.
- PRAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GORECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both marketsRECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration ("TGA") and has been listed on New Zealand's Web Assis
- PRAVITA Medical to Announce First Quarter 2026 Financial ResultsVALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve
- SECSEC Form DEF 14A filed by Avita Medical Inc.DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationRecognition highlights pioneering contributions to modern burn care including development of RECELL® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA). The award, the ABA's highest honor, recognizes individuals whose enduring contributions have advanced burn care, research, and education. Professor Wood was presented with the award during a ceremony at the ABA 2026 Annual Meeting. "Professor Wood not only has a remarkable legacy of achi
- PRAVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin GraftingMean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction)Median time to graft of 11 days, with grafting as early as 5 daysStudy ongoing with full dataset expected in 2026Management to host Key Opinion Leader webinar at 4:30 p.m. ET on April 16 during the American Burn Association Annual Meeting VALENCIA, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thic
- SECSEC Form EFFECT filed by Avita Medical Inc.EFFECT - AVITA Medical, Inc. (0001762303) (Filer)
- SECSEC Form PRE 14A filed by Avita Medical Inc.PRE 14A - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency PreparednessAgreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a therapeutic acute wound care company, today announced it has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The agreement, awarded under Project BioShield and valued at up to $25.5 million, is intended to strengthen national preparedness for burn mass
- PRAVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx DataCohealyx® multi-center study interim analysis and new case data to be presentedRECELL® and PermeaDerm® data reinforce a comprehensive approach to wound healingEvidence demonstrates potential to improve outcomes while reducing hospital length of stay and optimizing resource utilization VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experien
- SECSEC Form S-3 filed by Avita Medical Inc.S-3 - AVITA Medical, Inc. (0001762303) (Filer)
- INSIDERSEC Form 4 filed by Avita Medical Inc.4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERSEC Form 3 filed by new insider Woody Joseph Fralin3 - AVITA Medical, Inc. (0001762303) (Issuer)
- ANALYSTNorthland Capital initiated coverage on Avita Medical with a new price targetNorthland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00
- INSIDERCFO O'Toole David D bought $12,450 worth of shares (3,000 units at $4.15), increasing direct ownership by 2% to 140,127 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- PRAVITA Medical to participate at the TD Cowen 46th Annual Health Care ConferenceVALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O'Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. AVITA Medical management is scheduled to participate in a presentation and fireside chat on Wednesday, March 4, at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. A live and archived webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentat
- INSIDERCFO O'Toole David D was granted 105,470 shares, increasing direct ownership by 333% to 137,127 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERChief Legal Officer Kelsey Nicole was granted 98,390 shares (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- PRAVITA Medical to Host Investor Webinar BriefingVALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O'Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover financial and business results from AVITA Medical's recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&A session. Participan
- SECSEC Form 10-K filed by Avita Medical Inc.10-K - AVITA Medical, Inc. (0001762303) (Filer)
- SECAvita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Reports Fourth Quarter and Full Year 2025 Financial ResultsVALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avita Medical Inc.SCHEDULE 13G/A - AVITA Medical, Inc. (0001762303) (Subject)
- PRData at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologiesFirst surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations
RCEL FAQ
6 questionsWhat does Avita Medical Inc. do?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells...Where does RCEL stock trade?
Avita Medical Inc. (RCEL) is listed on NASDAQ.What sector and industry is RCEL in?
Avita Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about RCEL?
Avita Medical Inc. has had 6 recent analyst actions on file. The most recent action was from Northland Capital: Outperform with a $1000.00 price target on 2026-03-05.What companies are similar to RCEL?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare RCEL side-by-side with any of them on Quantisnow.How can I track RCEL on Quantisnow?
Quantisnow aggregates Avita Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RCEL to receive live email and push alerts on every new disclosure.